Genmab — Juni 2015
-
Han er ved at blive lidt sød ham Frank
-
Resumeet fra ASCO har jo været fremme siden 30 maj - men havde ikke selv set denne tilføjelse ( Medscape), det har i måske, men her er den: "A response lasting 7.4 months in this population is quite remarkable," commented Suzanne Lentzsch, MD, PhD, director of the Multiple Myeloma and Amyloidosis Service at New York–Presbyterian Hospital/Columbia University Medical Center, in New York City. "This shows its potency in a heavily pretreated population."
"This is a study of 106 patients, which is
-
"This is a study of 106 patients, which is fairly large and straightforward and gives us insight into the single-drug activity with this agent," said Dr Lentzsch, who was approached by Medscape Medical News for independent commentary.
However, Dr Lentzsch believes that daratumumab will probably not be used as a single agent but as part of combination therapy. Daratumumab is currently being studied in several ongoing phase 3 trials that are exploring daratumumab in combination with various exist
-
However, Dr Lentzsch believes that daratumumab will probably not be used as a single agent but as part of combination therapy. Daratumumab is currently being studied in several ongoing phase 3 trials that are exploring daratumumab in combination with various existing regimens in different stages of the disease.
"The next step is to establish efficacy in combination with other agents and to bring it to frontline therapy," she said.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind